C-Reactive protein levels in patients with chronic obstructive pulmonary disease. Universidad de Chile. Correspondencia a:. This raise may be related directly to COPD and its associated systemic inflammation or secondary to other factors such as smoking status, disease severity, acute exacerbations, or associated complications. Patients and Methods: Cohorts of mild-to-very severe COPD patients 41 current smokers , 31 never-smokers, and 33 current smoker controls were compared. Being smoker did not influence CRPus levels.
|Published (Last):||5 May 2017|
|PDF File Size:||1.11 Mb|
|ePub File Size:||17.93 Mb|
|Price:||Free* [*Free Regsitration Required]|
C-Reactive protein levels in patients with chronic obstructive pulmonary disease. Universidad de Chile. Correspondencia a:. This raise may be related directly to COPD and its associated systemic inflammation or secondary to other factors such as smoking status, disease severity, acute exacerbations, or associated complications.
Patients and Methods: Cohorts of mild-to-very severe COPD patients 41 current smokers , 31 never-smokers, and 33 current smoker controls were compared. Being smoker did not influence CRPus levels. Using multivariate analysis FM, PaO 2 , and number of acute exacerbations of the disease in the last year had the strongest association with CRPus levels. It is weakly associated with fat mass, arterial oxygen tension and frequency of exacerbations.
Key words: Emphysema; C-reactive protein; Pulmonary disease, chronic obstructive; Systemic inflammatory response syndrome. En todos los participantes las mediciones se efectuaron en un lapso no mayor a una semana. Las correlaciones entre log PCRus y las diferentes variables analizadas se estimaron usando correlaciones de Pearson o Spearman, dependiendo de la naturaleza de la segunda variable. La obesidad y la presencia o riesgo de ECA fueron similares en ambos grupos.
Tabla 1. El log PCRus fue similar entre los sujetos controles nunca fumadores y fumadores y entre los pacientes con EPOC fumadores activos y ex fumadores. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Comorbidities in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc ; 5: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta- analysis.
Thorax ; Rennard SI. Inflammation in COPD: a link to systemic comorbidities. Eur Respir Rev ; Airway and systemic inflammation and decline in lung function in patients with COPD. Chest ; C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J ; Rosenberg SR, Kalhan R. Dying from, and with, chronic obstructive pulmonary disease. C-reactive protein: a critical update.
J Clin Invest ; The interactions between cigarette smoking and reduced lung function on systemic inflammation. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Systemic inflammation in chronic obstructive pulmonary disease: The role of exacerbations. Proc Am Thorac Soc ; 4: Systemic effects of chronic obstructive pulmonary disease.
Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med ; Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? Circulation ; Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease.
Chron Respir Dis ; 5: A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health ; Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders.
Prog Neurobiol ; Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care ; C-reactive protein in patients with COPD, control smokers and non-smokers. BMC medical genetics ; Six-minute walk test and maximum exercise test in cycloergometer in chronic obstructive pulmonary disease. Are the physiological demands equivalent? Arch Bronconeumol ; Evaluation of clinical methods for rating dyspnea. Toward a consensus definition for COPD exacerbations.
Chest ; SS. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA ; Standardisation of spirometry. Spirometric reference values from a sample of the general U. Rev Med Chile ; Pulmonary emphysema: Radiation dose and section thickness at multidetector CT quantification Comparison with macroscopic and microscopic morphometry. Radiology ; Peripheral muscle weakness in patients with chronic obstructive pulmonary disease.
Systemic inflammation among stable ex smokers with chronic obstructive pulmonary disease. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med ; C reactive protein and chronic obstractive pulmonary disease: a Mendelian randomisation approach. C-Reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD.
The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Agusti A, Soriano JB. Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship? Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis ; Body composition and plasma levels of inflammatory biomarkers in COPD.
Cardiovascular risk scores do not account for the effect of treatment: a review. Heart ; Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review.
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet ; The importance of cardiovascular disease for mortality in patients with COPD: a prognostic cohort study.
Family Practice ; Recibido el 31 de diciembre de , aceptado el 2 de enero de Alejandra Parada. Julieta Klaassen. Max Andresen. Carmen Lisboa. Servicios Personalizados Revista. Mediciones En todos los participantes las mediciones se efectuaron en un lapso no mayor a una semana. Tabla 2. Figura 2. Referencias 1. Correspondencia a: Dr. Marcoleta - Piso 1. Fax: E-mail: odiazp vtr. Figura 1.
2011, Número 4
Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J ;27 3 Global strategy for the diagnosis, managenent and prevention of chronic obstructive pulmonary disease. Last Updated The nature of small-airway obstruction in chronic obstructive pulmonary disease.
La palabra "progresiva" indica que la enfermedad empeora con el tiempo. Sin embargo, hasta el 25 por ciento de las personas con EPOC nunca fumaron. Si esto sucede, disminuye el intercambio gaseoso en los pulmones. La EPOC es una causa importante de discapacidad y ocupa el cuarto lugar entre las causas de muerte en los Estados Unidos. La EPOC aparece lentamente. La EPOC grave puede impedirle realizar incluso las actividades elementales, como caminar, cocinar o encargarse de su cuidado personal.
Chronic obstructive pulmonary disease COPD is a chronic disease causing increasing healthcare costs worldwide. Another respiratory disease causing high costs and morbidity is community-acquired pneumonia CAP. Because of the constant growth in the population with both diseases CAP and COPD , analyzing their clinical characteristics is important. Several cellular factors are known to contribute to differences in clinical expression: some lead to COPD exacerbations while others lead to symptoms of pneumonia. The use of new biomarkers procalcitonin, pro-adrenomedullin and copeptin help to distinguish among these clinical pictures. To decrease morbidity and mortality, clinical guidelines on antibiotic therapy must be followed and this therapy should be prescribed to patients with CAP and COPD. There are also prevention measures such as the pneumococcal vaccine whose role in the prevention of pneumococcal CAP should be further studied.